Lonza

Lonza, a pharmaceutical preparation manufacturing company headquartered in Switzerland (CH), has reported significant carbon emissions and set ambitious climate commitments. For the year 2025, Lonza's total reported emissions were approximately 2.71 billion kg CO2e. This total comprises approximately 317 million kg CO2e from Scope 1 emissions, about 93 million kg CO2e from Scope 2 (market-based), and roughly 2.30 billion kg CO2e from Scope 3 emissions. Within Scope 3, purchased goods and services accounted for the largest portion, at approximately 1.53 billion kg CO2e.

In 2024, the company's total emissions were around 2.36 billion kg CO2e, with Scope 1 at approximately 343 million kg CO2e, Scope 2 (market-based) at about 141 million kg CO2e, and Scope 3 at approximately 1.88 billion kg CO2e.

Lonza has made a commitment to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% by 2030, using 2021 as the base year. This commitment aligns with a 1.5°C trajectory and has been validated by the Science Based Targets initiative (SBTi). Furthermore, Lonza aims for a 50% reduction in total waste per revenue by 2030, compared to 2018 levels, and has a broader ambition to achieve net-zero by 2050 or earlier. The company is actively working to reduce its GHG emissions intensity, with targets to reduce this by below 50% by 2030 compared to 2010 levels. Lonza is also engaging its suppliers, aiming for 79% of suppliers by emissions to have science-based targets by 2028.